Nuvectis Pharma (NVCT)
(Delayed Data from NSDQ)
$6.40 USD
-0.27 (-4.05%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $6.40 0.00 (0.00%) 5:02 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.40 USD
-0.27 (-4.05%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $6.40 0.00 (0.00%) 5:02 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
Wall Street Analysts See a 229.34% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 229.3% in Nuvectis Pharma (NVCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Down -36.49% in 4 Weeks, Here's Why You Should You Buy the Dip in Nuvectis Pharma, Inc. (NVCT)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Nuvectis Pharma, Inc. (NVCT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
New Strong Buy Stocks for July 10th
by Zacks Equity Research
CRBG, LSF, SMWB, NVCT and WT have been added to the Zacks Rank #1 (Strong Buy) List on July 10, 2023.
Here's Why Momentum in Nuvectis Pharma, Inc. (NVCT) Should Keep going
by Zacks Equity Research
Nuvectis Pharma, Inc. (NVCT) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Zacks.com featured highlights Corsair Gaming, Nuvectis Pharma and WisdomTree
by Zacks Equity Research
Corsair Gaming, Nuvectis Pharma and WisdomTree have been highlighted in this Screen of The Week article.
3 Best Breakout Stocks Worth Buying for Superlative Returns
by Tirthankar Chakraborty
Invest in breakout stocks such as Corsair Gaming (CRSR), Nuvectis Pharma (NVCT) & WisdomTree (WT) as of now for solid returns.
Here's What Could Help Nuvectis Pharma, Inc. (NVCT) Maintain Its Recent Price Strength
by Zacks Equity Research
Nuvectis Pharma, Inc. (NVCT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Wall Street Analysts Think Nuvectis Pharma, Inc. (NVCT) Could Surge 29.35%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 29.4% in Nuvectis Pharma, Inc. (NVCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.